FDA Permanently Removes In-Person Dispensing Requirement for Medication Abortion

Pregnancy Experts Applaud Change which will Allow Greater Access to Abortion Care

December 17, Washington, DC – The Society for Maternal-Fetal (SMFM) released the following statement in response to the U.S. Food and Drug Administration's (FDA) review of restrictions on mifepristone and decision to permanently remove the in-person dispensing requirements.

“SMFM supports an individual’s right for reproductive choice. Mifepristone is a key agent for an individual's ability to pursue a medication abortion. The U.S. Food and Drug Administration (FDA) has permanently removed the in-person dispensing requirement on mifepristone. The removal of this restriction allows patients seeking medication abortion to access appropriate care via telehealth and receive the medication by mail. SMFM supports the FDA’s decision to remove this outdated restriction and will continue to advocate for the repeal of other restrictions that remain in place on mifepristone and act as barriers to quality healthcare.”

About SMFM
SMFM The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients.